GlobeNewswire Inc | Sep 2, 2020 04:30PM EDT

September 02, 2020

Montrouge, France, September 2, 2020

DBV Technologies to Participate in Multiple September Investor Conferences

DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the following virtual investor conferences in September:

Citis 15th Annual BioPharma Virtual Conference, September 9-10.DBVs management team will participate in virtual investor meetings at the conference.

Goldman Sachs 10thAnnual Biotech Symposium, September 11. DBVs management team will participate in virtual investor meetings at the conference on Friday, September 11.

H. C. Wainwright 22nd Annual Global Investment Conference, September 14-16.Daniel Tass, Chief Executive Officer, will participate in a fireside chat at the conference on Tuesday, September 15 at 10:00 AM ET.

Morgan Stanley 18th Annual Global Healthcare Conference, September 14-18.Daniel Tass, Chief Executive Officer, will participate in a fireside chat at the conference on Wednesday, September 16 at 8:45 AM ET.

A live webcast of each of the presentations at the H. C. Wainwright 22nd Annual Global Investment Conference and the Morgan Stanley 18th Annual Global Healthcare Conference will be available on the Investors & Media section of the Companys website: https://www.dbv-technologies.com/investor-relations/. A replay of each presentation will also be available on DBVs website after the respective event.

About DBV TechnologiesDBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut (DBV712). DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Companys ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Companys ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Relations Contact Anne PollakDBV Technologies+1 857-529-2363anne.pollak@dbv-technologies.com

Media ContactAngela MarcucciDBV Technologies+1646-842-2393angela.marcucci@dbv-technologies.com

Attachment

-- PDF Version